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This paper describes a framework for the risk assessment of combined exposure to multiple chemicals
based on and developed subsequent to the World Health Organization/International Programme on
Chemical Safety Workshop on Aggregate/Cumulative Risk Assessment (Combined Exposures to Multiple
Chemicals) held in 2007. The framework is designed to aid risk assessors in identifying priorities for risk
management for a wide range of applications where co-exposures to multiple chemicals are expected. It
is based on a hierarchical (phased) approach that involves integrated and iterative consideration of expo-
sure and hazard at all phases, with each tier being more reﬁned (i.e., less cautious and more certain) than
the previous one, but more labor and data intensive. It includes reference to predictive and probabilistic
methodology in various tiers in addition to tiered consideration of uncertainty. The paper also annexes
two case studies that have been developed to test and reﬁne the framework.
 2011 World Health Organization. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
A World Health Organization (WHO)/International Programme
on Chemical Safety (IPCS) Workshop on Aggregate/Cumulative Risk
Assessment (Combined Exposures to Multiple Chemicals) was held
in Washington, DC, USA, on 19–21 March 2007. The principal
objectives of the workshop, which involved experts from agencies
worldwide, were to consider the state of the art in this area and
delineate next steps. The workshop report, which comprises an
overview and a series of extended abstracts, serves as a resource
to identify existing methodologies in this area (IPCS, 2009a).
Workshop participants recommended additional consideration
of terminology in order to facilitate communication internationally
in this area and development of an international framework for the
risk assessment of combined exposures to multiple chemicals. Thisshed by Elsevier Inc.
f an international group of
ns or the stated policy of the
h Organization (WHO), 2011.
has granted the publisher
Open access upaper describes the framework based on and developed by a draft-
ing group subsequent to the WHO/IPCS workshop and references
associated case studies, included at the end of this paper and else-
where (EFSA, 2009), developed to test and reﬁne the framework.
The draft framework was revised based on feedback received dur-
ing a public comment period from May to October 2009 and a
WHO review meeting (see Acknowledgments).
The framework is designed to aid risk assessors in identifying
priorities for risk management for a wide range of applications
where co-exposures to multiple chemicals are expected. Applica-
tion of the framework is not conﬁned to any particular type of
chemical or effect. The framework builds on previously published
guidance for priority setting and assessment of combined expo-
sures (see, for example, Meek and Armstrong, 2007; US EPA,
2007). It is intentionally concise, based on the recognition that
more extensive guidance on speciﬁc technical aspects, including
data quality, is available (ATSDR, 2004; US EPA, 2007; IGHRC,
2009). The framework is designed to be additionally developed
through pragmatic application in speciﬁc case studies.
The case studies annexed to this paper were developed to illus-
trate application of the framework. They are considered to be only
examples of a much broader range of potential applications, whichnder CC BY-NC-ND license.
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for and extent of remediation of sites contaminated by a range of
environmental contaminants.
The framework is being published at this time to increase expe-
rience in its application. Illustration of the application of the frame-
work through additional case studies is invited and anticipated in
planned follow-up activities. Comments based on experience with
its use are welcomed and should be submitted to the correspond-
ing author.2. Terminology
At the WHO/IPCS Workshop on Aggregate/Cumulative Risk
Assessment (Combined Exposures to Multiple Chemicals) held in
Washington, DC, in March 2007, it was recommended that termi-
nology to describe various aspects of exposure to and effects of
multiple chemicals be as precisely descriptive as possible. Working
deﬁnitions for key terms and concepts developed at the workshop
are included here as background to the framework. For clarity, it is
recommended that the italicized terms below be used when apply-
ing this framework for the risk assessment of combined exposure
to multiple chemicals.
Exposure to the same substance from multiple sources and by
multiple pathways and routes is likely best described as ‘‘single
chemical, all routes’’ (referenced in some jurisdictions as ‘‘aggre-
gate’’ exposure). Similarly, it is recommended that exposure to
‘‘multiple chemicals by a single route’’ be distinguished from expo-
sure to ‘‘multiple chemicals by multiple routes’’ (referenced in some
jurisdictions as ‘‘cumulative’’ exposure). To this end, this frame-
work addresses ‘‘combined exposure to multiple chemicals’’—i.e.,
exposure to multiple chemicals by a single route and exposure to
multiple chemicals by multiple routes. Substances grouped to-
gether for evaluation of combined exposure are referenced as an
‘‘assessment group.’’
Chemicals that act by the same mode of action and/or at the
same target cell, tissue or organ often act in a potency-corrected
‘‘dose additive’’ manner. Alternatively, chemicals may act indepen-
dently, by discrete modes of action or at different target cells, tis-
sues or organs (independent joint action). Chemicals may also
interact to produce an effect greater than that predicted on the ba-
sis of additivity (comprising synergy) or an effect less than that pre-
dicted on the basis of additivity (comprising antagonism).
Relevant also to the framework for risk assessment of combined
exposure to multiple chemicals is a common understanding of
‘‘mode of action,’’ which has been deﬁned previously by IPCS. A pos-
tulated mode of action is a biologically plausible sequence of key
events leading to an observed effect supported by robust experi-
mental observations and mechanistic data. It describes key cyto-
logical and biochemical events—i.e., those that are both
measurable and necessary to the observed effect (Sonich-Mullin
et al., 2001). It does not imply full understanding of mechanism
of action at the molecular level.
Combined exposure to multiple chemicals is also deﬁned in the
context of whether or not the components act by similar or differ-
ent modes of action in induction of critical effects (i.e., ‘‘single mode
of action’’ or ‘‘multiple modes of action’’). The terms ‘‘simple mix-
tures’’ and ‘‘complex mixtures’’ are often used by some authors
to refer to combined exposure to multiple chemicals that act by
similar and different modes of action, respectively. Other authors
use the very same terms (i.e., ‘‘simple mixtures’’ and ‘‘complex
mixtures’’) to distinguish mixtures with limited numbers of sub-
stances from those with large numbers of substances or to distin-
guish mixtures of known composition from those of unknown or
variable composition. To avoid confusion, these terms are not used
in this framework.3. Purpose and focus of a framework assessment
A framework for the risk assessment of combined exposure to
multiple chemicals has been developed to maximize efﬁciency in
the consideration and generation of available information. The
objective of framework analyses is ‘‘ﬁt for purpose’’ assessment,
to ensure that no more resources are invested than are necessary
to make a decision for the purpose at hand—namely, to set an
assessment group aside as a nonpriority for further consideration
or to inform risk management. This is based on a hierarchical
(phased) approach that involves integrated and iterative consider-
ation of exposure and hazard at all phases, with each tier being
more reﬁned (i.e., less conservative and uncertain) than the previ-
ous one, but more labor and data intensive. In addition to conserv-
ing resources in assessment, the approach is helpful in focusing
research in critical areas (see, for example, United Kingdom
Committee on Mutagenicity of Chemicals in Food, Consumer
Products and the Environment, 2008)
The level of effort required for assessment is also tailored to the
magnitude of potential risks, the objective (e.g., priority setting or
screening for additional focus or risk management) and scope (e.g.,
local and national), addressed at the outset in problem formula-
tion. Problem formulation requires preliminary consideration of
hazard characterization and exposure assessment as a basis to plan
the risk assessment process.
There are many reasons why a risk assessment of combined
exposure to multiple chemicals might be necessary, and only some
examples are provided here and in the case studies annexed to this
paper to illustrate the potential utility of the framework. The pur-
pose of the present paper is to describe a general approach for risk
assessment of combined exposure to multiple chemicals that can
be adapted to the needs of speciﬁc users. Example situations where
a risk assessment for combined exposure to multiple chemicals
might be necessary include emissions of multiple substances from
a common source (e.g., a landﬁll site); the presence of multiple
substances in surface waters; establishing a maximum residue
level for a pesticide, exposure to which will occur together with
exposure to similar pesticides; exposure to multiple substances
in food or pollutants in the atmosphere; and exposure to a formu-
lated multicomponent chemical product (e.g., paint).
Available methodology for conducting assessments for com-
bined exposure to multiple chemicals is described in more detail
in a range of publications (see, for example, US EPA, 2007; Euro-
pean Commission, 2010). Methods are based on consideration of
exposure to and effects of speciﬁc similar combinations of compo-
nents that have been studied collectively (i.e., whole combina-
tions), or they are based on consideration of their components.
For the latter, which is more common, different approaches are
based on the assumptions of dose additivity (where components
are considered to be toxicologically similar), response additivity
(where components are considered to act independently) and
interaction (where effects of combined exposure to components
are expected to be greater than or less than those based on the
assumption of dose additivity). For dose additivity, approaches
are normally based on summed indices of comparison of estimated
exposure with hazard for components (e.g., the hazard index).
Alternatively, they are based on summed estimated exposure to
components adjusted by potency, relative to an index compound
(i.e., relative potency factors).4. Considering a framework analysis for an assessment group
The potential impact of co-occurrence of, and concomitant
exposure to, multiple chemicals should always be taken into
account in problem formulation for any risk assessment.
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analyses are addressed within the following questions.
 What is the nature of exposure? Are the key components known?
Are there data available on the hazard of the mixture itself (i.e.,
not extrapolated from the hazards presented by the components
of the mixture)?
Lack of information on these aspects precludes a framework
analysis. This does not, however, obviate the need potentially to
introduce riskmanagement measures to reduce exposure, although
recognizably in the absence of a robust science basis to inform the
process.
 Is exposure likely, taking into account the context?Is the use proﬁle of the substances in the assessment group such
that exposure is not expected? For example, are the substances
used only as industrial intermediates and not expected to be re-
leased to the general environment? Are they diluted or degraded
in the environment, or is absorption precluded because their
molecular weights are large? If the response to these questions
suggests that exposure is unlikely, then further assessment in a
framework analysis for combined exposure is not required.
 Is there a likelihood of co-exposure within a relevant timeframe?
Do the temporal aspects of external exposure, toxicokinetics
and toxicodynamics preclude co-exposure to the compounds of
interest? For example, do the compounds in the assessment group
have short half-lives (kinetics) or effects of short duration (dynam-
ics)? Is the time between initial and subsequent exposures for such
compounds sufﬁcient so as to preclude co-exposures? Alterna-
tively, will products containing the chemicals be used at the same
time? If not, there may not be relevant co-exposures. If, based on
consideration of these aspects, the likelihood of co-exposure is
low, a framework analysis of an assessment group is unnecessary.
On the other hand, biomonitoring data may indicate co-
occurrence of substances in the human body or elimination
products. Such data indicate the potential relevance of their
consideration in a framework analysis for an assessment group.
 What is the rationale for considering compounds in an assessment
group?The decision to consider compounds in an assessment group is
commonly based on information indicating that the components
co-occur and/or are believed to act similarly or interact. Normally,
it would be based on predictive information on chemical structure,
such as structure–activity relationships (SARs), quantitative struc-
ture–activity relationship (QSAR) modeling, structural alerts or,
alternatively, data on hazard or other biological data (toxicity or
efﬁcacy) that lead to the conclusion that effects are likely to be
similar. For example, are effects observed in the same target or-
gans? Is the biological outcome the same? Are the chemicals used
for similar application (e.g., antioxidants and molting inhibitors),
which might potentially imply similar modes of action, or do they
co-occur at a contaminated site?5. The framework
A conceptual representation of the framework is included in
Fig. 1.
The point of departure (POD) is a selected measure of effect. It
may be a no-observed-(adverse-)effect level (NO(A)EL) or lowest-
observed-(adverse-)effect level (LO(A)EL) or a dose or concentra-tion associated with a speciﬁed increase in the incidence of an ef-
fect (e.g., a benchmark dose [BMD10] or concentration [BMC10]
associated with a 10% increase in incidence of an effect).
The margin of exposure is the ratio of the selected measure of
effect to the estimated exposure dose or concentration.
Components of the framework are described in more detail be-
low. However, in considering the content of both the ﬁgure and the
supporting text, it is important to understand that included tiers
are provided principally as examples. They are not ﬁxed and will
vary, depending on available data. There may also be additional
iterations of the tiers.
As indicated in Fig. 1, then, following consideration of the ques-
tions in problem formulation, the initial tier begins with simple but
conservative assumptions for both exposure and hazard. These
assumptions are reﬁned and replaced with increasingly detailed
data and models, but only if necessary. Thus, if there is no cause
for concern based on assessment at the initial tier using conserva-
tive defaults, no further resources are invested. However, if the re-
sults of an initial, conservative assessment indicate excessive risk,
then the assessment is reﬁned, incorporating more data and more
accurate models.
At any tier, the outcome of margin of exposure analysis can be
risk management, no further action, generation of additional data
or further assessment (i.e., additional reﬁnement in a higher tier).
The evaluation of the adequacy of the margin of exposure is depen-
dent on the actual purpose and/or (legal) framework for which the
assessment is performed. Factors such as interindividual variation
(including susceptible groups), interspecies differences, quality
and robustness of the database, nature of the hazard and temporal
aspects should be taken into account (see IPCS, 2009b, for addi-
tional guidance). Approaches to consideration of the adequacy of
themargins of exposure should be conservative, but commensurate
with the degree of uncertainty at each tier (see IPCS, 2008, for guid-
ance on characterizing uncertainty in exposure assessment).
In this framework, dose additivity is the default assumption for
estimating risk in all tiers. The use of dose additivity is considered
conservative based on analysis of empirical results for effects of
combined exposure including to chemicals that induce critical ef-
fects by different modes of action (US EPA, 2007; EFSA, 2008; Euro-
pean Commission, 2010). In addition, in the small number of cases
where it has been reported that dose additivity may underpredict
effects as a result of synergistic interaction, recent analyses of lim-
ited available data suggest that the magnitude of the underpredic-
tion is less than an order of magnitude (Kortenkamp and Hass,
2009; European Commission, 2010).
Two example case studies have been prepared to illustrate the
application of this framework for the risk assessment of combined
exposure to multiple chemicals. The ﬁrst case study (case study A:
Annex A) is based on an existing screening assessment for polybro-
minated diphenyl ethers. The second is a ﬁctionalized example, for
a range of substances that co-occur in drinking water, utilizing the
threshold of toxicological concern (case study B: Annex B). These
case studies are considered to be only examples of a much broader
range of potential applications. As some aspects for all have been
additionally developed or modiﬁed, the case studies do not repre-
sent actual assessments of the chemicals themselves, but rather
are designed to be illustrative in the context of application of the
framework. This approach has also been illustrated by the
European Food Safety Authority (EFSA) in consideration of triazole
pesticides (EFSA, 2009).
5.1. Tier 0
5.1.1. Exposure assessment
Where the margins between very crude, conservative estimates
of exposure and points of departure for hazard are large, simple
Fig. 1. A conceptual representation of the framework (see text for details).
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components of an assessment group may be sufﬁcient as a basis
for an early-tier analysis. Semiquantitative estimates are based
on limited data and a few very simple assumptions. Information
on indicators of potential exposure, such as volume, use and/or
physicochemical properties, is often combined to provide mea-
sures of relative ranking, which can then be quantiﬁed crudely
based on comparison with more robust quantitative estimates for
chemicals with similar proﬁles.
For example, in the categorization of the 23000 substances on
the Canadian Domestic Substances List, each of the substances on
the list was relatively ranked (from 1 to 23000) based on volume
of production, the numbers of producing and/or using companies
and the sum of ‘‘expert ranked uses.’’ Expert ranking for the latter
was based on the extent to which the uses were considered to con-
tribute to potential exposure of the general population, derived
from several workshops involving relevant experts (Health Canada,
2006).
Another example of semiquantitative estimates is the budget
method for food additives. In this method, exposure to food addi-
tives is crudely estimated based on assumptions regarding physio-
logical requirements for energy and liquid and on the energy
density of food, rather than on speciﬁc surveys on food consump-
tion (Douglass et al., 1997).
Alternatively, such estimates can also be based on information
on sales, percentage composition of compound in a product and
the number of users, providing rough worst-case estimates.Semiquantitative estimates may be additionally reﬁned through
inclusion of information on physicochemical properties (e.g., infor-
mation on vapor pressure provides an indication of whether or not
particular uses are likely to lead to emissions to air).
5.1.2. Hazard assessment
As a conservative early assumption, based on an indication that
components of an assessment group should be considered together
(e.g., target organs are similar or mode of action might be similar,
based on predictive hazard tools such as SAR or QSAR), particularly
in the absence of information on individual components, it is often
assumed that all components have the same potency as the most
toxic compound known (see, for example, US EPA, 2000).
5.1.3. Risk characterization
Where reference values for components are available, it may be
possible to incorporate the individual health-based guidance
values (e.g., reference dose, allowable operator exposure level,
acceptable daily intake, tolerable daily intake, and critical derived
no-effect level) as a basis for comparison of potencies using the
hazard index. A hazard index is the sum of the exposures to each
of the component compounds of an assessment group divided by
their respective reference values. As such, it represents risk-based
summation of exposures to individual components, adjusted by
their relative hazard. In a Tier 0 assessment, this is normally based
on adjustment for all components by the reference value for the
most toxic of the component compounds.
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doses are not strictly comparable, being based on reviews of vary-
ing datasets in different periods, for different critical effects and
with inconsistent application of uncertainty factors by different
regulatory agencies. However, the hazard index is considered to
be conservative and protective, given the common underlying
premise of being based on critical effects occurring at lowest dose.
Depending on the basis for the reference doses, the uncertainty
associated with different hazard indices will vary considerably
and needs to be explicitly addressed in interpreting the adequacy
of the margin between estimated exposure and hazard (see, for
example, Lambert and Lipscomb, 2007).
5.2. Tier 1
5.2.1. Exposure assessment
For a Tier 1 assessment, summation of deterministic estimates
of exposure for all components of the assessment group based on
measured or modeled data, or both, may sufﬁce as a basis for com-
parison with a measure of hazard to determine whether further
assessment is necessary. These estimates are commonly based on
broad, conservative scenarios addressing a range of somewhat sim-
ilar uses with limited numbers of parameters being included. For
example, for the evaluation of cosmetics in the European Union,
a default exposure to 17.8 g of all cosmetic products per day (with-
out distinction) is used in generic estimates (European Commis-
sion, 2006).
5.2.2. Hazard assessment
In a Tier 1 assessment, the analysis is reﬁned by incorporating
additional information on the potency of individual components
for the common effect and more accurate measures of points of
departure for hazard. For example, rather than reference values
for which the timeframe of development, critical effects and uncer-
tainty factors may not be comparable, points of departure on the
dose–response curve (e.g., LOAELs or NOAELs) for common critical
effects may be used as a basis to estimate relative potency. Use of
benchmark doses instead of effect levels for critical effects also in-
creases precision somewhat additionally for the point of departure.
5.2.3. Risk characterization
Risk characterization can be undertaken by calculating the haz-
ard index (i.e., sum of the ratios of estimated exposures to refer-
ence values for component compounds in the assessment group).
Rather than using the reference value of the most potent of the
components for all substances, as in a Tier 0 assessment (see Sec-
tion 5.1.3), exposure can be adjusted by the reference value for
each individual compound. The hazard index can be additionally
reﬁned by using reference values adjusted for the common effect
in the calculation (see, for example, Lambert and Lipscomb, 2007).
Alternatively, a point of departure index can be calculated. A
point of departure index is the sum of exposures divided by the
point of departure for each of the individual components of an
assessment group and, as such, represents risk-based summation
of exposures to individual components. It overcomes a potential
difﬁculty of the hazard index, in that it avoids incorporation of dif-
ferent uncertainty factors that may have been used in the deriva-
tion of reference values, for reasons unrelated to the common
effect.
Risk is determined from the magnitude of the index. For com-
parison, the acceptable hazard index for a single substance would
be 1 or less. The acceptable point of departure index for a single
substance would be 0.01 or less, assuming the same default
assumptions as used in deriving the reference value (i.e., common
uncertainty factor of 100 when based on data from experimental
animals). The margin between estimated exposure and hazard isconsidered in the context of associated uncertainties as a basis to
determine whether or not a higher-tier assessment is required
(see, for example, IPCS, 2008, 2009b). The nature of considerations
that constituted the basis for determining that a higher-tier assess-
ment is or is not required (i.e., adequacy of the margin of exposure
in the context of uncertainty associated with both estimated expo-
sure and hazard) is explicitly stated.
5.3. Tier 2
5.3.1. Exposure assessment
In Tier 2 assessments, the deterministic estimation of exposure
is reﬁned with incorporation of increasing numbers of measured
values. Exposure scenarios are better deﬁned (i.e., more tailored
to the speciﬁc situation under consideration). Models may incorpo-
rate additional parameters, and, although estimates are still con-
sidered conservative, they are believed to be more realistic,
incorporating more data. Multiple sources are often taken into ac-
count by summation.
5.3.2. Hazard assessment
In Tier 2 assessments, the deﬁnition of an assessment group
may be additionally reﬁned through consideration of increasingly
more speciﬁc information on mode of action or other factors on
which to base the grouping (e.g., molecular modeling). For some
substances (e.g., cholinesterase inhibitors), this may be at the level
of a molecular target. In addition, availability of measures of po-
tency for each of the components of the assessment group permits
the derivation of relative potency factors. The potency of each com-
ponent is expressed as an equivalent of that for an index com-
pound (i.e., the point of departure of an index compound divided
by the point of departure of the compound of interest), with the
latter being selected on the basis of the most robust and reliable
database.
5.3.3. Risk characterization
Where it is possible to derive relative potency factors, risk is
determined by expressing the sum of the relative potency factor-
adjusted exposures to all substances in the group as a percentage
of the reference value of the index compound. If combined expo-
sure is 100% or less of the reference value, exposure would be con-
sidered acceptable, by analogy with that of a single substance. As
with Tier 1, the margin between estimated exposure and hazard
is considered in the context of associated uncertainties as a basis
to determine whether or not a higher-tier assessment is required
(see, for example, IPCS, 2008, 2009b). The nature of considerations
that constituted the basis for determining that a higher-tier assess-
ment is required (i.e., adequacy of the margin of exposure in the
context of uncertainty associated with both estimated exposure
and hazard) is explicitly stated.
5.4. Tier 3
5.4.1. Exposure assessment
In Tier 3 assessments, estimates of exposure are probabilistic in
nature, taking into account distributions of exposure factors or
exposure data. This approach requires representative information
on exposure for the scenarios of interest for the relevant popula-
tions for different uses and across populations. Models at this level
of complexity often include multiple-source exposures.
5.4.2. Hazard assessment
Tier 3 assessments of hazard incorporate increasingly reﬁned
information on mode of action, including both kinetic and dynamic
aspects. These can include both physiologically based pharmacoki-
netic (PBPK) and biologically based dose–response (BBDR) models,
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ization of some aspects of kinetic and dynamic variability and
uncertainty. In application of PBPK models, concentrations of sub-
stances need to be adjusted to take into account differences in haz-
ard (i.e., potency). One possibility is the use of relative potency
factors, as deﬁned above. These models, which incorporate both
chemical-speciﬁc and more generic information on comparative
physiology, biochemistry, etc., improve the characterization of
interspecies differences and human variability (i.e., as a basis for
extrapolation across species and among humans).5.4.3. Risk characterization
In probabilistic assessments, risk can be estimated as the per-
centile of the population exceeding the reference value, as the
maximum exceedance of the reference value or as the percentage
of the population at or below the reference value for a given per-
centile of the distribution (e.g., 99.9th percentile). It may be sufﬁ-
cient to report these values to risk managers, but often some
guidance for interpretation will be necessary. This will require
agreement as to what percentiles are considered acceptable by risk
managers. In PBPK approaches, it should be possible to determine a
point of departure and compare this with the sum of the estimated
potency-corrected internal concentrations of the substances being
assessed.
The margin between estimated exposure and hazard is consid-
ered in the context of associated uncertainties as a basis to deter-
mine whether or not clear recommendations can be made to risk
managers or whether there are sufﬁcient data gaps for further re-
search that could enable reﬁnement of the assessment (see,
for example, IPCS, 2008, 2009b). The nature of considerations
that constituted the basis for determining that further research
would be helpful in reﬁning the assessment is explicitly stated,
together with a description of the type of research that would be
of value.6. Discussion
In developing case studies for application of the framework, no
examples were identiﬁed where combined exposure had been sys-
tematically and hierarchically addressed as a basis to conserve re-
sources. Indeed, readily available assessments of combined
exposure were restricted principally to higher-tier considerations.
In considering these (often) higher-tier assessments for prepara-
tion of the case studies that appear at the end of this paper, it is
clearly evident that the tiered approach to framework analysis
has the potential to considerably reduce the resources required
to assess combined exposure.
In addition, while the limited availability of case examples may
be a function of the lack of regulatory requirement to consider
combined exposure or, alternatively, to a lack of their publication,
the need for additional advancement in this area continues to be
emphasized by stakeholders. Given constraints on resources as
well as the need to be addressing large numbers of individual
compounds more efﬁciently, the framework described herein has
considerable potential to contribute in this context, given its
health-protective and resource-conserving nature, based on the
considerable degree of conservatism in early tiers.
Appropriate application of the framework as a basis to consider
combined exposure also contributes to increased transparency
through the requirement to explicitly consider uncertainties in
decision-making.
Based on limited experience in application of the current frame-
work, it is considered that the hazard assessment tiers are fairly
easily adapted to available data or information that can be gener-
ated speciﬁcally for the purpose. Additional experience in frame-work analyses is also likely to lead to delineation of data
requirements for exposure, as that would maximally conserve re-
sources in regulatory programs.
A variety of additional case studies would further illustrate, test
and develop the framework, which is expected to evolve. This
would be best facilitated by continued sharing of experience in
the conduct of assessments of combined exposure, as a basis to in-
form strategies for additional development (which scenarios to ad-
dress?) for possible regulatory applications.
Illustration of the application of the framework through addi-
tional case studies is, therefore, invited and anticipated in planned
follow-up activities. The European Centre for Ecotoxicology and
Toxicology of Chemicals (ECETOC) has led the development of an
additional case study on carbamates, based upon an available US
EPA assessment, which will be published subsequent to the pres-
ent paper. Additional case studies are anticipated to be developed
by partner institutions and experts, including experts from the Per-
sistent Organic Pollutants Review Committee of the Stockholm
Convention on Persistent Organic Pollutants.
The additional case studies will aim to illustrate different appli-
cations of the framework, with the objective of facilitating its
understanding and use by risk assessment institutions and, ulti-
mately, its further development.Acknowledgments
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Example case study A: PBDEs
M.E. (Bette) Meek ⇑
McLaughlin Centre, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada K1N 6N51. Introduction
An example of a framework analysis for a screening assessment
conducted under the Canadian Environmental Protection Act is pre-
sented here. The assessment group is polybrominated diphenyl
ethers (PBDEs). While based, in part, on a chemical-speciﬁc assess-
ment, some aspects have been changed to illustrate speciﬁc as-
pects of the World Health Organization (WHO)/International
Programme on Chemical Safety (IPCS) framework for the risk
assessment of combined exposure to multiple chemicals. As a re-
sult, the example presented here does not represent an assessment
of any speciﬁc chemicals per se.
The tiers of assessment for this assessment group are illustrated
conceptually in Fig. A.1.
2. Considering the need for a framework analysis
Relevant data are considered here as a basis to determine
whether a framework analysis is appropriate and the potential
nature of the assessment group.
 What is the nature of exposure? Are the key components known?
Are there data available on the hazard of the mixture itself?The focus of this assessment is consideration of the risk of expo-
sure of the population in the general environment, including
through consumer products, as a basis to consider whether subse-
quent risk management is required. The majority of identiﬁed data
relevant to the evaluation of human health risk relate to the com-
mercial mixtures, with much less information being available for
individual congeners.
Uses of PBDEs in Canada are similar to those in other coun-
tries, primarily as additive ﬂame retardants in a wide variety of
consumer products, such as internal electric/electronic compo-
nents of and casings for household appliances/electronics (e.g.,
hair dryers, televisions, and computers), furniture upholstery
and cushioning, and wire and cable insulation. The three main
commercial mixtures containing the seven isomers that were
the subject of the assessment are commercial pentabromodiphe-
nyl ether (PeBDE), or ComPeBDE (usually containing a mixture of
PBDEs with 4–6 bromines); commercial octabromodiphenyl ether
(OcBDE), or ComOcBDE (usually containing a mixture of PBDEs
with 6–9 bromines); and commercial decabromodiphenyl ether
(DeBDE), or ComDeBDE (usually containing PBDEs with 9–10
bromines).
 Is exposure likely, taking into account the context?
Yes. There is potential for exposure of the general population
through direct contact with products containing these PBDEs.
The general population is also potentially exposed to PBDEs in
the environment through the use and disposal of these products.
 Is there a likelihood of co-exposure within a relevant timeframe?
Fig. A.1. Conceptual illustration of tiers of analysis for PBDEs.
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tures and reason to believe that their kinetics will be similar, based
on similarity in physicochemical properties.
 What is the rationale for considering compounds in an assessment
group?
The assessment group contains seven isomers with identical
base structure, overlap in congeners within the commercial mix-
tures, similarities in uses and common target organs. Trends in
physicochemical properties and toxicity vary consistently with
increasing degree of bromination.3. Purpose and focus of the assessment
This case study addresses a screening-level risk assessment for
PBDEs conducted under the Canadian Environmental Protection Act.
Several PBDEs were identiﬁed as meeting criteria speciﬁed
within regulations under the relevant legislation for persistence
and/or bioaccumulation. They were also considered to be ‘‘inher-
ently toxic’’ to non-human organisms. On this basis, they were
nominated for inclusion in a pilot phase for preparation of a
screening assessment.
PBDEs are a class of substances containing an identical base
structure that differ in the number of attached bromine atoms
(n = 1–10). Selection of the seven PBDE congener groups consid-
ered in this assessment was based on their potential use in
Canada (i.e., their designation as existing substances included on
the Domestic Substances List) (Table A.1). The three main commer-Table A.1
List of PBDEs considered in the assessment (Health Canada, 2006).
Congener group Acronym Number of individual congeners
Tetra TeBDE 42
Penta PeBDE 46
Hexa HxBDE 42
Hepta HeBDE 24
Octa OcBDE 12
Nona NoBDE 3
Deca DeBDE 1cial mixtures containing these seven isomers are ComPeBDE (usu-
ally containing a mixture of PBDEs with 4–6 bromines), ComOcBDE
(usually containing a mixture of PBDEs with 6–9 bromines) and
ComDeBDE (usually containing PBDEs with 9–10 bromines).4. The framework analysis
Having determined that a framework analysis is appropriate
and (at least) the initial composition of an assessment group, avail-
able data are considered in a tiered (hierarchical) and integrative
(considering both exposure and hazard) fashion, relying in early
stages on crude and conservative estimates as a basis to determine
whether additional assessment or data generation is required. In
each of the tiers, estimates of exposure and measures of potency
are developed and compared and uncertainties considered. The
margin between estimated exposure and hazard is considered in
the context of associated uncertainties as a basis to determine
whether or not a higher-tier assessment is required. The nature
of considerations that constituted the basis for determining that
a higher-tier assessment is required (i.e., adequacy of the margin
of exposure in the context of uncertainty associated with both esti-
mated exposure and hazard) is explicitly stated.
4.1. Tier 0
4.1.1. Exposure assessment
A semiquantitative measure of exposure was available for
these substances, developed on the basis of the relative ranking
of PBDEs during the categorization of all substances on the
Domestic Substances List under the Canadian Environmental Pro-
tection Act. In this exercise, potential for exposure was deter-
mined based on the volume of production, the numbers of
producing and/or using companies and the sum of ‘‘expert ranked
uses.’’ Expert ranking for the latter was based on the extent to
which the uses were considered to contribute to potential expo-
sure of the general population, derived from several workshops
involving relevant experts.
On this basis, four of the congeners (tetrabromodiphenyl ether,
or TeBDE; PeBDE; hexabromodiphenyl ether, or HxBDE; and
heptabromodiphenyl ether, or HeBDE) were considered to present
‘‘lowest potential for exposure of the general population in Can-
M.E. Meek et al. / Regulatory Toxicology and Pharmacology 60 (2011) S1–S14 S9ada’’; three of the congeners (OcBDE; nonabromodiphenyl ether, or
NoBDE; and DeBDE) were considered to present ‘‘intermediate po-
tential for exposure of the general population.’’ Semiquantitative
measures of exposure were developed through comparison of rel-
ative rankings, physicochemical properties and use patterns with
substances for which deterministic estimates of exposure were
available.
4.1.2. Hazard assessment
In view of the absence of reference or tolerable intakes or con-
centrations for the relevant congeners, a hazard index (i.e., the sum
of exposures divided by the reference value for each of the individ-
ual components of an assessment group) could not be developed.
4.1.3. Risk characterization/analysis of uncertainties
As these summed semiquantitative estimates of exposure ex-
ceeded a conservative measure of hazard (i.e., the lowest-ob-
served-effect level [LOEL] for the most toxic congener), additional
assessment was considered necessary (see Section 4.2.2).
4.2. Tier 1
4.2.1. Exposure assessment
Available data upon which to base estimates of population
exposure to PBDEs are quite disparate, ranging from concentra-
tions in speciﬁc media for individual congeners or congener groups
to concentrations of total PBDEs, without further identiﬁcation of
speciﬁc congeners. In view of the limitations of the data with
which to estimate exposure to individual congeners or congener
groups and the limited objectives of a screening assessment, con-
servative upper-bounding estimates of total intake of PBDEs were
derived based on maximum levels in air, water, dust, food and hu-
man breast milk and standard intake values for six age groups
within the Canadian population.
Based on reported concentrations of PBDEs in ambient and in-
door air, water, various foodstuffs, human breast milk and dust,
along with standard reference values for intake, an upper-bound-
ing estimate of daily intake of total PBDEs (i.e., the tetra to deca
congeners considered here) ranged from 0.2 to 2.6 lg/kg body
weight per day for six different age groups of the general popula-
tion, including breastfed infants, in Canada (Health Canada,
2006). Food (including breast milk) represents the principal source
of exposure for the majority of the age groups (although dust was
the principal source of exposure for the 0–6-month-old nonbreast-
fed infants). The age group with potentially the greatest exposure
was 0–6-month-old breastfed infants, with breast milk accounting
for 92% of the exposure.
These upper-bounding estimates of exposure were considered
conservative, in that they were based on summed estimates forTable A.2
Overview of critical health effects and effect levels for PBDE congener groups and comme
Congener group LOEL (mg/kg body weight per
day)
End-point
TeBDE 11 Developmental: behavioral (m
PeBDE 0.8 Developmental: behavioral (m
HxBDE 0.9 Developmental: behavioral (m
HeBDE – –
OcBDE – –
NoBDE – –
ComPeBDE 2 Liver histopathology: subchro
(rat)
ComOcBDE 5 Liver weight: subchronic diet
ComDeBDE,
DeBDE
2.2 Developmental: behavioral (m
a Personal communication from H. Viberg regarding abstract from the Second Inte
Substances Division, Health Canada, Ottawa, Ontario, dated 29 November 2002.all congeners for which data were available and highest mea-
sured concentrations for many media. Quantitative implications
of this degree of conservatism were taken into account in deter-
mining the adequacy of the margin of exposure (see
Section 4.2.3).
Upper-bounding estimates of intake in food for subpopulations
consuming more traditional or country foods were not substan-
tially greater (i.e., less than twofold). Similarly, estimates of intake
from dermal contact with dust or oral contact with household
products treated with ﬂame retardants containing the penta and
octa congeners were also negligible in comparison with intake
from food (Health Canada, 2006).
4.2.2. Hazard assessment
The majority of identiﬁed data on the toxicity of PBDEs relate to
the commercial mixtures, with much less information being avail-
able for individual congeners. Although a full range of toxicity
studies was not available for all congeners or commercial mixtures,
target organs and endpoints for the PBDEs are similar, including
the liver, the thyroid and early behavioral development. Based on
preliminary assessment of the available toxicological data, the crit-
ical effects and effect levels for the ComPeBDE, ComOcBDE and
ComDeBDE mixtures, as well as for each of the congener groups
considered in this assessment (where possible), are presented in
Table A.2. Critical effects of PBDEs were those that occur on the
liver and on neurobehavioral development. Owing to the limited
nature of the database for some substances, conﬁdence in the
assessment for each PBDE congener group and commercial mixture
varies.
The selected critical effect level was the conservative value of
0.8 mg/kg body weight (for PeBDE), based on neurobehavioral ef-
fects consisting of changes in locomotion, rearing and total activity
in a dose- and time-related manner observed in neonatal mice
administered a single oral dose by gavage on postnatal day 10
and observed for a subsequent 5-month period. Selection of this
critical effect level was supported by additional information on
similar effects being observed in mice exposed to the penta conge-
ner by maternal administration and in neonatal mice administered
single, relatively low doses of the tetra, hexa and deca congeners
by the same investigators. A somewhat lower LOEL of 0.44 mg/kg
body weight per day for ComPeBDE, based on alterations in hepatic
enzyme activities, was not considered critical based on the lack of
observation of histopathological changes in the liver at this or
higher doses (Health Canada, 2006).
4.2.3. Risk characterization/analysis of uncertainties
As a basis for development of conservative margins for the pur-
poses of screening and in light of the similarity of health effects
associated with the various PBDEs considered here, the selectedrcial products (Health Canada, 2006).
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mate of exposure to total PBDEs (i.e., the tetra to deca congeners
considered here) for the potentially most highly exposed subgroup.
Comparison of the critical effect level (i.e., 0.8 mg/kg body
weight for neurodevelopmental effects in mice following neonatal
exposure) with the upper-bounding deterministic estimate of
exposure for the intake of total PBDEs (2.6 lg/kg body weight
per day in breastfed infants) resulted in a margin of exposure of
approximately 300.
Margins based on available biomonitoring data were approxi-
mately 10-fold less. These were estimated through back-calcula-
tion of intakes by ﬁrst-order kinetic modeling of limited data on
levels in blood of the general population and comparison of esti-
mated body burden for the critical study in experimental animals
with that for breastfed infants. However, conﬁdence in these esti-
mates was considered to be less, owing to the considerable limita-
tions of the relevant data on biological half-lives of PBDEs in
humans and their seeming inconsistency with what would be ex-
pected based on relevant physicochemical properties.
The degree of conservatism in this margin is relevant to its
interpretation. One critical aspect is the large interindividual vari-
ability in levels of PBDEs in breast milk within the general popula-
tion. It should be noted that mean and median levels of PBDEs in
breast milk were as much as 400- and 200-fold less, respectively,
than the maximum levels on which the estimates of exposure were
based. In addition, the critical effect level with which the estimate
of exposure was compared was that for the most sensitive effect
for the most toxic congener. In comparison, effect levels in chronic
studies for the same congener were approximately 100 times
greater than that used to calculate the margin of exposure.
The margin of exposure does not, however, take into account
the potential continuing increase in body burden of PBDEs (based
on data for breast milk), should similar use patterns continue.
Based on limited data, levels of PBDEs in human breast milk in Can-
ada appear to be increasing with time (e.g., there was a ninefold in-
crease in mean concentration between 1992 and 2001). Prediction
of trends in body burdens is precluded by the limited information
on the toxicokinetics of PBDEs in humans and experimental ani-
mals and transfer from human breast milk to infants, as well as
the uncertainty in half-lives for removal processes for PBDEs in
environmental media.
Determination of the adequacy of the derived margin to address
elements of uncertainty associated with limitations of the database
for health effects and population exposure (in which conﬁdence
overall is considered to be moderate), intraspecies and interspecies
variations in sensitivity, as well as the biological severity of the ef-
fects deemed critical was found to require additional in-depth
evaluation of the relevant data. Development of additional, moremeaningful information on population exposure to PBDEs was also
considered desirable.
However, in view of the smaller margin between the most con-
servative estimated critical values for exposure and effects on the
environment in comparison with that for human health and result-
ing recommended action to protect the environment, in-depth
evaluation of PBDEs from a human health perspective was consid-
ered a low priority at this time.
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Improvements in analytical methodology have resulted in the
routine detection of a diverse range of substances representing
various chemical classes, often at very low levels, in surface water.
As a result, surface water represents a real-world example of a
complex mixture. Many of the substances present do not have
established chronic health standards or health-based guidance val-
ues, such as tolerable daily intakes; indeed, for some of the compo-
nents in the particular mixture, there might be little or no
information on their toxicity. Investigation of these mixtures using
higher-tier assessments would require considerable resources and
a signiﬁcant number of data.
The intent of this case study is to illustrate the potential utility
of applying the threshold of toxicological concern (TTC) approach
in a Tier 0 assessment to prioritize the need for further evaluation
of a chemical mixture. This case study uses the Cramer et al. (1978)
classes, which have been used to deﬁne three potency bins for non-
cancer endpoints in the TTC approach. The approach assumes that
the only information available is (1) the identities and structures of
the chemicals in the mixture and (2) their respective levels in sur-
face water. Based on these two pieces of information, it should be
possible to use the TTC approach (Kroes et al., 2004) as a Tier 0
assessment tool.
The TTC approach sets a de minimis value below which expo-
sure is considered unlikely to be a concern, based upon structural
characteristics of the chemical in question and existing toxicity
data for other substances in an identiﬁed database. The database
was developed by Munro and colleagues (1996) and draws upon
work by Cramer et al. (1978) that divides low molecular weight or-
ganic chemicals into three classes by analyzing toxic, noncarcino-
genic effects according to chemical structure. Chemicals that are
potentially genotoxic (on the basis of prediction or measurement)
are considered a separate class, with their own TTC value. Some
chemical structures are excluded a priori from the TTC approach,
including certain potent genotoxic compounds (e.g., aﬂatoxin-like,
azoxy and N-nitroso compounds), as well as polyhalogenated di-
benzo-p-dioxins and dibenzofurans, steroids, proteins and nones-
sential metals (Kroes et al., 2004). The TTC approach has been
applied to food safety assessments, and additional work is ongoingq This publication contains the collective views of an international group of
experts and does not necessarily represent the decisions or the stated policy of the
World Health Organization.  Copyright World Health Organization (WHO), 2011.
All rights reserved. The World Health Organization has granted the publisher
permission for the reproduction of this article.
⇑ Corresponding author. Fax: +1 202 659 3617.
E-mail address: membry@ilsi.org (M. Embry).to investigate its potential application to mixtures in general, as a
Tier 0 approach.
This case study is based on data from Lee et al. (2004). Data on
observed concentrations of chemicals are used to create a hypo-
thetical mixture of 10 compounds. However, the mixture does
not reﬂect any speciﬁc sample from the Lee et al. (2004) survey,
nor does it take into account whether co-occurrence was observed.
The 10 chemicals fall into various classes, such as fragrances, pes-
ticides, surfactants, personal care products, solvents and
petrochemicals.
This case study assumes dose addition, where all components
are considered to contribute to the toxicity of the mixture. How-
ever, this approach does not explicitly address the possibility of
synergy. As discussed in the WHO/IPCS framework document,
the use of dose additivity is considered conservative based on anal-
ysis of empirical results for effects of combined exposure including
to chemicals that induce critical effects by different modes of ac-
tion (US EPA, 2007; EFSA, 2008; European Commission, 2010). In
addition, in the small number of cases where it has been reported
that dose additivity may underpredict effects as a result of syner-
gistic interaction, recent analyses of limited available data suggest
that the magnitude of the underprediction is less than an order of
magnitude (Kortenkamp and Hass, 2009; European Commission,
2010).
In a recent exercise, the International Life Sciences Institute
(ILSI) Health and Environmental Sciences Institute (HESI) per-
formed a literature review focused on ﬁndings of synergy at or near
doses associated with a study’s points of departure (e.g., the bench-
mark dose [BMD] and no-observed-effect level [NOEL]) that may
be associated with the development of chronic health-based guid-
ance values of individual mixture components. This review found
few studies that reported a quantiﬁed value for synergy at the
low doses used; from those studies, the maximum potential mag-
nitude of synergy did not exceed approximately fourfold (e.g., less
than four times that predicted based on an assumption of dose
addition). However, most of the studies included in the review
were performed at doses that caused overt toxic effects from acute
exposures (Embry et al., 2009; Boobis et al., 2011). The additive
model is expected to exclude exposures to such levels. Although
the examples identiﬁed in this review were not sufﬁcient to sup-
port robust conclusions regarding the frequency with which syn-
ergy is likely to occur following low-dose chronic exposures,
these results might indicate an upper-bound estimate when
screening of untested mixtures for synergistic potential. It has
yet to be determined how such information should inform a Tier
0 risk assessment.
Assumptions were intentionally selected to be conservative—
i.e., to result in a hazard index (HI) that would overestimate rather
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ing water ingestion. As a Tier 0 case study, the study design was
such that the emphasis was not on developing highly certain quan-
titative estimates of risk, but rather to utilize a conservative ap-
proach to demonstrate safety (HI < 1) with a low chance of false
negatives. In addition, this screening-level approach demonstrates
a more efﬁcient approach that would obviate the need for a more
detailed, resource-intensive, higher-tier evaluation.2. Considering the need for a framework analysis
The World Health Organization (WHO)/International Pro-
gramme on Chemical Safety (IPCS) framework for the risk assess-
ment of combined exposure to multiple chemicals presents a
series of questions designed to determine whether it is appropriate
to group substances in an assessment group for, in this example, a
Tier 0 screening-level risk assessment.
 What is the nature of exposure? Are the key components known?
Are there data available on the hazard of the mixture itself?
The purpose of the Tier 0 assessment is to serve as an initial
screening-level approach, to aid prioritization of those assessment
groups that should be subject to higher-tier assessments (e.g., Tiers
1, 2 and 3) and those that are expected to be of lesser concern. This
tier is intended to be conservative and often relies on semiquanti-
tative estimates of exposure based on very limited data. For the
purposes of the example, the identity of the individual components
and estimates of their exposure values are known from surface
water monitoring data, but there are no available data on the mix-
ture itself. Human exposure via consumption of the water is the
exposure pathway considered.
 Is exposure likely, taking into account the context?
For the purposes of this example, it is assumed that exposure of
the general population is possible via direct consumption of sur-
face water as drinking water.
 Is there a likelihood of co-exposure within a relevant timeframe?
The 10 substances were detected in surface waters in the same
survey. For the purposes of this example, the 10 substances are as-
sumed to occur simultaneously and continuously in the water.
Hence, there is potential co-exposure within a relevant timeframe.Table B.1
Surface water concentrations and estimated drinking water exposures for a hypothetical 1
Compound Concentration in surface
water (lg/L)
Concentration in surface
water (mg/L)
Exposure (m
weight per d
A 1.7 1.7E03 4.0E05
B 0.28 2.8E04 6.5E06
C 1.1 1.1E03 2.6E05
D 0.083 8.3E05 1.9E06
E 3.8 3.8E03 8.9E05
F 34 3.4E02 7.9E04
G 0.076 7.6E05 1.8E06
H 0.13 1.3E04 3.0E06
I 0.18 1.8E04 4.2E06
J 6.1 6.1E03 1.4E04
Hazard index (sum of hazard quotients)
a Obtained by dividing the respective TTC values for the appropriate Cramer class (180
kilograms), to express the values per unit of body weight. What is the rationale for considering compounds in an assessment
group?
All of the compounds utilized in this hypothetical example have
been detected in surface water and are therefore considered within
an assessment group as a worst-case scenario for a Tier 0
assessment.
3. Purpose and focus of the assessment
This case study addresses a Tier 0 screening-level risk assess-
ment for substances detected in surface water to determine
whether there is a possible human health concern from the con-
sumption of such water.
4. The framework analysis
4.1. Tier 0
4.1.1. Exposure assessment
Concentrations of the 10 substances are provided in Table B.1.
Although the concentrations are derived from actual monitoring
data, for the purposes of this illustrative example, the identities
of the substances are not provided. The following assumptions
were made regarding this exposure:
 All 10 substances are present at all times in the water at the
concentrations shown.
 One hundred percent of drinking water consumption comes
from this single source.
 Average exposure values for children (based on consumption
and body weight) were used, given the conservatism built in
by the assumption in this case study of lifetime chronic
exposure.
 The maximum detected concentrations of the contaminants in
water samples were used to derive exposure levels.
For illustrative purposes, exposure values for children via drink-
ing water are used given the higher exposure per kilogram body
weight for children compared with adults as a conservative
assumption. These values are estimated based on average con-
sumption of 0.42 L of water per day by an 18 kg child (aged 3–
6 years) (US EPA, 2008):
Exposure ðmg=kg body weight per dayÞ
¼ Surface water concentration ðmg=LÞ  0:42 L=day
18 kg0-compound mixture of surface water contaminants.
g/kg body
ay)
Cramer
class
TTC valuea (mg/kg body
weight per day)
Hazard quotient
based on TTC
I 0.03 1.3E03
I 0.03 2.2E04
I 0.03 8.7E04
II 0.009 2.1E04
II 0.009 9.9E03
II 0.009 8.8E02
III 0.0015 1.2E03
III 0.0015 2.0E03
III 0.0015 2.8E03
III 0.0015 9.3E02
0.20
0, 540 and 90 lg/day for classes I, II and III, respectively) by 60 (adult body weight in
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body weight data for any speciﬁc age group of interest or as a life-
time exposure by weighting age-speciﬁc exposures.
4.1.2. Hazard assessment
This Tier 0 example assumes that no toxicological information,
other than structure, is available for the detected substances. A
Cramer classiﬁcation of each of the 10 substances was performed
using ToxTree version 1.60 (http://ecb.jrc.ec.europa.eu/qsar/
qsar-tools/index.php?c=TOXTREE) (Table B.1). The assumption
was made that none of the compounds was genotoxic or excluded
from the TTC approach (e.g., aﬂatoxin-like, azoxy and N-nitroso
compounds, polyhalogenated dibenzo-p-dioxins and dibenzofu-
rans, steroids, proteins, high molecular weight chemicals such as
polymers and nonessential metals).
The TTC approach relies on conservative daily exposure thresh-
olds for each Cramer class, derived from a database of subchronic,
chronic and reproductive/developmental oral toxicity data on
more than 600 chemicals (Munro et al., 1996). The most conserva-
tive NOEL values were plotted based on structural class, and values
corresponding to the 5th percentile NOEL were selected, multiplied
by 60 kg (average adult body weight) and divided by an uncer-
tainty factor of 100 to calculate the human exposure threshold
(i.e., TTC) values of 1800 lg/day (Cramer class I), 540 lg/day (Cra-
mer class II) and 90 lg/day (Cramer class III). To use these TTC val-
ues for comparison with exposures of populations other than
adults, the values should be converted back into units of milli-
grams per kilogram of body weight per day. Accordingly, Cramer
class I chemicals have human exposure threshold values of
0.03 mg/kg body weight per day; class II, 0.009 mg/kg body weight
per day; and class III, 0.0015 mg/kg body weight per day (Barlow,
2005).4.1.3. Risk characterization/analysis of uncertainties
Hazard quotients (HQ) for each mixture component can be cal-
culated by dividing the exposure values (as shown in Table B.1) by
the respective TTC value:
HQindividual substance ¼
Exposureindividual substance ðmg=kg body weight per dayÞ
TTC valueindividual substance ðmg=kg body weight per dayÞ
A hazard index (HI) for the mixture can be calculated, assuming
dose addition for all components, by taking the sum of the individ-
ual hazard quotients:
HImixture ¼ HQA þHQB þHQC þHQD    þHQJ
Higher-tier assessment would not be a high priority if the hazard
index is less than 1. Utilizing the hazard index in this way corrects
exposure values based on estimates of chemical potency using Cra-
mer classiﬁcation.
Alternatively, compounds can be ﬁrst grouped by Cramer class
to simplify the equation above. For example, exposure values from
compounds A, B and C (class I) are added and divided by the TTC for
class I (0.03 mg/kg body weight per day), exposure values from
compounds D, E and F are added and divided by the TTC for class
II (0.009 mg/kg body weight per day) and exposure values from
compounds G, H, I and J are added and divided by the TTC for class
III (0.0015 mg/kg body weight per day). These three values are then
added to determine the total hazard index for the mixture.
As shown in Table B.1, the calculated hazard index of 0.20 is less
than 1. Therefore, the results of this Tier 0 assessment would sug-
gest that advancement to higher assessment tiers is not necessary
in this case.
As stated above, assumptions were intentionally selected to be
conservative—i.e., to result in a hazard index that would overesti-mate rather than underestimate risk for a chronic lifetime expo-
sure via drinking water ingestion:
 For this case study, the highest measured concentrations were
used, which is a conservative assumption.
 All analytes were assumed to be constantly present in the water
sample (see Section 2). This was a conservative approach to deal
with variation in presence over time.
 All drinking water was assumed to be from the single source
containing all analytes in question (see Section 4.1.1). This
was a conservative approach and does not consider that people
generally obtain water from more than one source.
 On a per kilogram body weight basis, children have greater
water consumption than adults (see Section 4.1.1). The average
drinking water consumption rate of a child was used, which is
greater than a chronic lifetime drinking water intake on a per
kilogram body weight basis. Alternative consumption rates
could be utilized.
 The TTC is a conservative approach. Each TTC value represents
the 5th percentile NOEL of all compounds in the dataset for that
particular class (i.e., 95% of the compounds in the class were less
toxic), with uncertainty factors of 100 applied. This case study
utilized the TTC value for each mixture component and
assumed dose addition for all Cramer classes (rather than
independence).
 The use of dose additivity is considered conservative based on
analysis of empirical results for effects of combined exposure
including to chemicals that induce critical effects by different
modes of action (see Section 1).
Given the conservative choices made to address the stated
uncertainties discussed above and a calculated hazard index of less
than 1, there is no need to conduct a higher-tier analysis for this
case study.
5. Conclusions
This hypothetical case study demonstrates the potential utility
of applying the TTC approach as a Tier 0 assessment tool for chem-
ical co-exposures. Additional case studies are planned to further
evaluate the performance of a TTC-based screening approach for
co-exposures.
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